News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
News Nuvalent buy delivers new cancer approval for GSK GSK has its first approval from the $10.6bn takeover of Nuvalent, ROS1+ NSCLC therapy Jideytro, which becomes the company's first lung cancer product.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
